General Comments: IDEX Health & Science is a global supplier of critical components, subsystems, and optics to, among others, the Analytical chemistry instrumentation industry.

5f [52 34 2EN2 iz ~ gg si2 H%IT8%HE15R2% Ef ie 2 55 g8% =: 5% 152 535 ; < 23 : gge ([sfe | : Vm 33 2 gf 8 3 1TT 7 of =7| of 3% EH 3E%r Vlg gg e#i3e5s5: 8 " i ERf HE2 da v [a 3 43LI i a 153% i$i5t35 3FEEs] HE EEE|) a2d g eT 5} 8 lef fa: SSE. fiir fz g HE 3g8i 5& Sffsf 2 32 EoFEiE n 3 82] FEES HE i42 32: sips gsfst SEE 332I 3o73 33 g2 ER : i 5 2& 5 >: 33 88 3: EFII Es E 2 8 gS 5 fF 2: = Ss. 53 2 EESE.S 20s B%P HGIg 8 43% 58% tf i 83 2 o :Ss 3E5$i88oe55%os 8 $233 E 2 $F f3csBsy 4 fo Sf 3 Xo8E5R.i5e2 38 Pi 283gLfs 335 52 2EE8CiB:: 3 , BEciifis EPiC E$8a8s8e5s 2EsC5 pTe3si5Ei0gz8Ei5ds8 td Eggresd 5288 o8n BgEgEgEfEgEs g: 25 385 Q aoB3x2Rg8f%f3s82 g2p EeaEfRarrEguEersEe 3Of 255 fz 3 og :55% & $f5S 52S98583c:23ig5Fisu:sk : | 58 & ET: |B: Ts 3: <38 <[252 <s3 =2g 8583 45% g (dE le | [1 | { Ld ee y #2 || 5% I -2 .8 8 of w |e3 8 139% | @ | E- g og 5 J 3 g 4 38 fd s: EE [44 5a2E x3gz $F 32 i: oi if HitE osfn| l[34 g| 2 i: HEHEHE ITH g8 5go5t3 s & 12 gis f F5 B83t f 0: os 20g2 ie:s EE $$s5: 32 ai:d 52 2 33 - zs: 53 z 2g:f 5 I3f 3g 3%2 85 3go% | 2Tg 3% : =i% : s $y 3 5z 0g 83 f#t7F 8: %8% 2 gq sf LS z TE 2 af A gg PF oif fk 2g88f:3 o53i7: :2 Es3eS3 fe 3 23% 3% s3 2 @ 5 8% 9g 8 FFFF 238% 5 g8%.e. 85:5 5 zS=isgizc2eEd8 3 TEC prigEE oo 2B:F fEE.SgEfsssSi3izilis 3 2$H c5 FZig3ssfifi8pEiggfo4ts8sztEe::ct Bi opezdpIiy oo 5% F300 CEES 8 gg 23 sg & 28 3 E88

Input to the Public Consultation Comments for Annex XV restriction Proposal.

09/22/2023 Additional information to general comment in response of the public consultation on the proposed EU restriction for PFAS Reference number of the previous answer : 4962d054-b85a-4c8d-bee7-a85b6042a92b GICAT, The French Land Defence and Security Industry Association responded previously to this public consultation to express its great concern about the proposal restriction of Per-and Polyfluoroalkyl substances (PFAS) that strongly impact its members.

Pilot-Scale Fluoropolymer Incineration Study: Thermal Treatment of a Mixture of Fluoropolymers under Representative European Municipal Waste Combustor Conditions Dr.

Fluororesin Products for Magnetic flow meters.

Apr 25, 2023 Comment on Proposed Restriction of PFAS Conference of Fluoro-Chemical Product Japan (FCJ) On behalf of chemical manufacturers, we, Conference of Fluoro-Chemical Product Japan (FCJ), have been working tirelessly to comply with national chemical regulations.

Eingabe des VDMA e.V.

WOUND HEALING WITH FIFLOW AA In vivo confocal observations of acne scars reduction process with Fiflow AA Oxygen: a wound-healing advance Alain SAINTROND Jaana PRINTZ Marion NOUVET The Innovation Company, Dreux, France (2018) INTRODUCTION Acne vulgaris is the most common type of acne skin disease.

But Upton spoke for the bill and challenged many of his GOP colleagues.

is a D4 siloxane and it may be an impurity from the synthesis of the main siloxane surfactant.

Draft agenda for PFAS-RESTRICTION WEBEX Meeting between DE, DK, NL, NO, SE CA and ECHA and COM 18 May, 9:00 - 13:00 (CET) Login details: See below Point 1 - Opening and adoption of the agenda (9:00-9:10 am) Point 2 - Minutes and action points (9:10 - 9:25 am) 2021-05-10_PFAS RESTR-16 Minutes and APs_Draft of FINAL.docx 2021-05-10_List of open APs.docx Point 3 - Status of COM/ECHA restriction on firefighting foams (9:25 - 9:40 am) - Update on collaboration with universal PFAS restriction (ECHA) Point 4 - Status update WP1 (09:40 - 09:50 am) - Comments received from COM and AT CA - Next steps Point 5 - Status update WP3 (09:50 - 10:10 am) - Feedback from discussion in PBT-EG (NO CA) - Hazard evaluation of alternatives (UBA) - Next steps for borderline documents (ENV and HH) Point 6 - Status update WP4 (10:10 - 10:40 pm) - Update from meeting on 12 May 2021 (Exposure and emission calculation) - 2nd round questionnaire (document to be circulated by ) Point 7 - Status update WP7 and Essential Use (10:40 - 10:45 am) Point 8 - Exchange of literature/references (10:45 - 11:00 pm) - Endnote library creation for dossier (see: PFAS Handling of literature.docx, circulated with this mail) Break 11:00 - 11:20 am Join by meeting number Meeting number (access code): Meeting password: 7nERmY2dyf3 (76376923 from phones and video systems) Tap to join from a mobile device (attendees only) ,1637174604#76376923# Germany Toll Some mobile devices may ask attendees to enter a numeric password.

dd Dec 20 WP WP0 DE/NL Responsible WP1 DE/NL Activities Coordination Preparation of Call for Evidence (including questionnaire and information document) in agreement between MS Call for Evidence (all MS and ECHA with news alerts and websites of all MS with Link to Helpdesk webpage) Preparation of Restriction option analysis document (all MS) RIME+ Dortmund 1st draft of restriction option analysis document (all MS) 2nd draft of restriction option analysis document (all MS) Finalisation of document, i.e. clarification of restriction options and scope (all MS) Restriction option analysis document to be uploaded on CIRCA (DE/ NL CA) RMOA-Conclusion, PACT-Update WP2 Drafting discussion paper NL Wordt vragenlijst + aanvulling 1e discussion paper WP3 DE/DK DE/DK WP4 NL/DE Verwerken commentaren van NO, SE, DE, I&W en RIVM deskundigen Coordination and alignment Pre-phase for environmental and human health hazard assessment --> Overview of relevant hazards (besides persistence) and generation of draft lists of substances for assessment Assessment phase --> Draft text for restriction proposal WP5 NO WP6 SE/DE Overview analytical methods (ch E7) Overview human and environmental monitoring data Working plan Design template for collection of monitoring date Presentation of slide WP6 at RiME Meeting wieh NCSU Collect monitoring data - ENV Collect monitoring data - HUM RiME FEB-2021 WP7 Scoping essential use NL Scoping impact assessment Baseline and restriction scenario(s) Economic impact assessment Environmental impact assessment Health impact assessment Assessment of other impacts Proportionality analysis Monthly meetings starts 2nd version questionnaire Draft of information document (DE/NL CA) Commenting round (all MS) Revision and draft of 3rd version of questionnaire and information document for WebEx (DE/NL CA) Detailed discussion of questionnaire and information document (all MS) Webex Final version (DE/ NL CA) Notification into PACT (DE/ NL CA) Discussion of responses received so far, data (all MS) Webex Decision on meetings with industry (all MS) DDiescciusisosnioonnowf rheiscthrircetisotrnicstcioonpeopantidonospstihoonusld(ablleMpSre) sWenetbeedx and discussed in RiME+ (all MS) Meetings with stakeholders and industry Presentation on RMOA for RiME May 2020 Contributions of first drafts of document parts according to lead in work packages and sub-work packages (all MS) Merge of contributions, redrafting (DE/ NL CA) Redrafting by all MS Merge of contributions, redrafting (DE/ NL CA) 31-Mar-20 4-May-20 August/September 2020 20/21 October 2020 25-Sep-20 5-Oct-20 19-Oct-20 Last redrafting by all MS Finalisation (DE/ NL CA) Commenting (by all other MS not part of group) Consideration of comments/if needed redrafting of document (DE/ NL CA in agreement with group) Webex meeting for initial discussing based on broad definition (NL, DE, SE, DK, NO, ECHA, COM) 1st discussion paper prepared by NL Face-to-face meeting (NL, DE, SE, DK, NO, ECHA, COM) based on discussion paper 2nd discussion paper prepared by NL (before RiME+) 26-Oct-20 10-Nov-20 23 - 27 November 2020 1-Dec-20 4-Jan-21 Discussion during RiME+ meeting Final discussion paper prepared by NL 2021 - TO BE PREPARED Kick-off meeting Joint HH/ENV progress meetings HH subgroup meetings ENV subgroup meetings Start up, Develop generic information basis for all sub-uses, structure of the sub-use reports (by WP7) - DONE Kick-off meeting (Discussion of content of each sub-use to avoid overlaps and discussion of revision of list of sub-uses and discussion of ETH Zrich work) - DONE 1 May 2020 1 Nov. 2020 Start up sub uses, Project plan fine tuning for sub-uses (and if needed tendering for consultants) Progress meeting after CfE is closed to check sub-uses, decide on stakeholder meetings (i.e. via mail) Stakeholder Meetings per sub-use: Follow up on information from CfE and to address knowledge gaps Sub-use studies (including gap analysis) Progress meeting Progress meeting Final reports consultants (& feedback to WP2) Integration of information (including gap analysis) Additional studies (i.e. membranes, processing aids?)

JOURNAL OF MULTI-CRITERIA DECISION ANALYSIS J.